Regeneron Pharmaceuticals Inc. said its non-GAAP net income for the fiscal fourth quarter ended Dec. 31, 2017, was $5.23 per share, compared with the S&P Capital IQ normalized EPS consensus estimate of $4.60.
EPS increased 72.0% year over year from $3.04.
Aggregate non-GAAP net income totaled $607.3 million, a gain of 72.3% from $352.5 million in the same quarter of 2016.
Total revenue grew 29% on an annual basis to $1.58 billion from $1.23 billion, and GAAP research and development expenses grew 10.2% year over year to $528.0 million from $479.2 million.
On a GAAP basis, net income fell 31.4% year over year to $173.5 million, or $1.50 per share, from $253.1 million, or $2.19 per share.
GAAP results account for a $326.2 million charge related to recently passed U.S. tax reform.
Full-year 2017 results
The Tarrytown, N.Y.-based company booked full-year 2017 non-GAAP net income of $16.32 per share, compared with the S&P Capital IQ normalized EPS consensus estimate of $15.68.
EPS rose from $11.32 in 2016.
Aggregate non-GAAP net income totaled $1.90 billion, an increase from $1.32 billion in 2016.
Full-year 2017 revenues were up 21% year over year to $5.87 billion.
On a GAAP basis, the company booked full-year 2017 net income of $1.20 billion, or $10.34 per share, which compared to $895.5 million, or $7.70 per share, in 2016.
